Skip to main content
Premium Trial:

Request an Annual Quote

DV Biologics, System Biosciences Ink Stem Cell Partnership

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DV Biologics and System Biosciences this week announced a partnership to develop human-derived, disease-specific induced pluripotent stem cell lines.

Under the terms of the deal, System Biosciences will convert many of DV Biologics' disease-specific cell types into iPSCs, using its proprietary products for reprogramming and iPSC generation, the two firms said in a statement.

System Biosciences will exclusively market several iPSCs developed under the agreement. No financial terms of the deal were disclosed.

DV Biologics is headquartered in Costa Mesa, Calif., and is a supplier of human primary cells and cell-derived products. System Biosciences is based in Mountain View, Calif., and develops and commercializes technologies for genomic- and proteomic-based investigations.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.